MAMMALIAN TOLLOID-LIKE GENE AND PROTEIN

Abstract: A mammalian gene encoding a tolloid-like protein distinct from human or murine BMP-1/mT1d and distinct from human or murine mT11-1 is presented. The gene is similar in structure to members of the BMP-1 family of genes, but maps to a distinct location and encodes a distinct protein having distinct activities. The protein encoded by the gene can be used to screen putative therapeutic agents in an ongoing effort to inhibit activity of the BMP-1 family of genes to prevent scarring, fibrosis, and the like.

Description: MAMMALIAN TOLLOID-LIKE GENE AND PROTEIN CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 60/111,873 filed December 11, 1998 and of U.S. Provisional Application No. 60/080,550 filed April 3, 1998. Each application is incorporated herein by reference in its entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT To be determined. BACKGROUND OF THE INVENTION The present invention relates to the field of bone morphogenetic proteins and more particularly to genes and proteins in the BMP-l/Tld family. Bone formation in mammals such as mice and humans is governed by a set of bone morphogenetic proteins (BMP) . Of the seven BMPs known to participate in osteogenesis, six (designated BMP-2 through BMP-7) belong to the TGF-β super family. The seventh BMP (designated BMP-1) is not TGF-β- like, but instead appears to derive from a different gene family. The BMP-1 gene family members typically contain the following domains: an astacin-like metalloprotease domain, one or more EGF-like motifs which in other proteins are thought to bind Ca ++ , and a number of CUB domains. A CUB domain is a motif that mediates protein-protein interactions in complement components Clr/Cls which has also been identified in various proteins involved in developmental processes. BMP-1 was described, at the nucleotide sequence level, by ozney, J.M. , et al . , Science 242:1528-1534 (1988). The mammalian BMP-1 domain structure is shared by proteins found in other non-mammalian species. These proteins include Drosophila tolloid (Tld) (Shimell, M.J., Cell 67:469-481 (1991)), a tolloid-like Drosophila gene product (Tlr-1 or tolkin) (Nguyen, T., Dev. Biol . 166:569- 586 (1994) and Finelli, A.L., et al . , Genetics 141:271-281 (1995)), a sea urchin BMP-1 homolog (suBMP-1) (Hwang, S.- P., et al., Development 120:559-568 (1994)), two related sea urchin developmental gene products, SpAN and BP10 (Reynolds, S.D., et al . , Development 114:769-786 (1992) and Lepage, T., et al . , Development 114:147-164 (1992)), a Xenopus BMP-1 (xBMP-1) (Maeno, M. et al . , Gene 134:257-261 (1993), a Xenopus tolloid (Lin. J. , et al . , Develop. Growth Differ. 39:43-51 (1997), a tolloid-like Xenopus gene product named xolloid (Piccolo, S. et al . , Cell 91:407-416 (1997) , a related member of the family isolated from zebrafish and called zebrafish tolloid (Bladder, P. et al . , Science 278:1937-1940 (1997), a mammalian tolloid (mTld) (Takahara, K. et al . , J. Biol. Chem. 269:32572-32578 (1994)) and a mammalian tolloid-like gene (mTll- 1) (Takahara, K. et al . , Genomics 34:157-165 (1996)). Some of the nucleic acid sequences of the genes that encode these proteins are known. The mammalian BMP1 gene encodes both the BMP-1 protein and the mTld protein, albeit on two distinct, alternately spliced mRNA molecules. The papers mentioned in this paragraph are incorporated herein by reference . BRIEF SUMMARY OF THE INVENTION The present invention is summarized in that a novel mammalian tolloid-like gene product (mTll-2) and its cognate polynucleotide gene, mTLL-2, are distinct from mTld and from all other known BMP-1-related gene products and their cognate polynucleotides, including mTll (now designated mTll-1) . The human and murine versions of the gene are reported herein as SEQ ID N0:1 and SEQ ID NO: 3, respectively. The amino acid sequences encoded by each are presented as SEQ ID NO: 2 and SEQ ID N0:4, respectively. It is an object of the present invention to provide a gene and gene product involved in the deposition of extracellular matrix in vertebrates (e.g., in osteogenesis) . It is another object of the present invention to provide a target molecule for rational development of a drug for inhibiting activity of the tolloid-like genes to treat fibrosis, scarring, keloids, surgical adhesions, and the like. It is yet another object of the present invention to provide a recombinant DNA construct, and a protein encoded by the construct, for use in accelerated wound and fracture healing. It is still another object of the present invention to provide markers that map to the 10q24 region of human chromosome 10 and to the distal end of chromosome 19 in mice. It is still another object of the present invention to provide nucleotide sequences that function as probes for a non-BMP-1 bone morphogenetic protein gene in mammalian cells . Other objects, features, and advantages of the present invention will become apparent upon consideration of the following detailed description considered in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS Fig. 1A-1C (together, "Fig. 1") aligns the deduced amino acid sequences of the disclosed mTll-2 human (htll-2) and murine (mtll-2) genes to those of the human mTld (humtolloid) and human mTll-1 (htll) genes. Alignment was performed using the PileUp program (Genetics Computer Group, Madison, Wisconsin) , with a GAP weight of 12 and GAP length weight of 4. The approximate endpoints of the protein domains are as indicated in provisional application serial number 60/080,550, incorporated herein by reference. DETAILED DESCRIPTION OF THE INVENTION Mammalian tolloid-like 2 (mTll-2) is a genetically distinct member of the subfamily of astacin-like proteases of which bone morphogenetic protein-1 (BMP-1) is the prototype. This subfamily of proteases, which also includes mammalian tolloid (mTld) and mammalian tolloid- like 1 (mTll-1; formerly referred to as mTll) , represents key control points in developmental and homeostatic processes, in wound healing, and in pathological processes such as fibrosis. The gene encoding mTll-2 has spatial and temporal expression profiles that differ from the other members of the BMP-1 family and is expressed in soft tissues at highest levels in adult and developing heart as ascertained by means of northern and master blots (Clontech) of RNA from developing and adult human and mouse tissues. The mTll-2 genes exemplified herein are particularly distinguishable from other members of the BMP- 1 family of genes at the 3 ' end of the coding sequence (which encodes the carboxy terminal 17 amino acids of the mTll-2 proteins) and in the section that encodes the proregion of the proteins. The proteins are similarly distinguishable from other proteins in the family. The inventors have determined that, unlike BMP-1, mTld and mTll-1, mTll-2 is not a procollagen C-proteinase and does not cleave chordin. mTll-2 weakly cleaves prolysyl oxidase to mature active forms. The protein may also cleave other substrates involved in matrix deposition, development, homeostasis, wound healing and disease. The mTll-2 protein will likely optimally cleave a subset of substrates different from those for which BMP-1, mTld and mTll-1 are optimal, despite some overlaps in substrate specificity with those proteins. mTll-2 is a potential target for anti-fibrotic drugs, may accelerate healing in various tissues, and is also useful for studying developmental and disease processes and for identifying its functional inhibitors. Inhibition of mTll-2 may inhibit fibrosis, excess scarring, or other derangements of normal healing or development. Use of recombinant mTll-2 (or its cognate nucleic acids) may be of use in systems for evaluating development, disease processes, and therapeutic intervention. The mTll-2 protei ^ ay act by activating growth factors and morphogens . As such, it may accelerate healing if added exogenously (or if cognate nucleic acids are added into cells, for example, in a genetic therapy) . Polynucleotides (e.g., genomic DNA, messenger RNA, and cDNA corresponding to messenger RNA) that encode mTll-2 can be amplified under suitable amplification conditions from a template library that comprises mammalian polynucleotides, using primers that correspond to conserved regions of the catalytic domains of previously reported astacin metalloproteases. The following degenerate oligonucleotide primers (shown using standard IUPAC nomenclature) are suitable for obtaining a portion of the mTll-2 gene, and are considered preferred by the inventors : Primer 1 (forward) : 5' -CARGCMATGMGNCACTGGGAG-3' (SEQ ID NO: 5) Primer 2 (forward) : 5 • -CARGCMATGMGNCACTGGGAA-3 ' (SEQ ID NO : 6) Primer 3 (reverse) : 5'-GAADGTGTTVCKNGCRTARTGC-3 ' (SEQ ID NO: 7) A suitable template library comprising mammalian polynucleotides is preferably a pool of unamplified cDNAs from human placenta or from mouse embryos 7 days post coitum. The cDNAs in the pool are preferably prepared by RT-PCR amplification of mRNAs . Suitable human and mouse placental and embryo cDNA pools are commercially available from Clontech. The source of the template cDNA is not critical, as long as the cDNA pool includes at least one template sequence that can be amplified as described. Other suitable templates can include, but are not limited to, an organ-specific or other type of cDNA pools or libraries or genomic DNA or library. Suitable amplification conditions are detailed in the Examples below, although one skilled in the art can determine acceptable conditions that differ from those reported herein. Once the initial PCR product is obtained, it can be used for plate screening of cDNA or genomic libraries . It may be necessary to separately establish the 5 ' or 3' end of the cDNA sequences encoding mTll-2 using, for example, a method that selectively amplifies only 5' or 3 ' end cDNA sequences, such as 3 ' -degenerate PCR or Rapid Amplification of cDNA Ends ( "RACE" ) , Frohman, M.A. "Rapid amplification of complementary DNA ends for generation of full-length complementary DNAs: Thermal RACE" in Methods in Enzymoloαy (Wu, R. , ed.) Vol. 218, pp. 340-362, Academic Press, New York (1991), incorporated herein by reference in its entirety. A commercial system for 5 ' and 3 ' RACE amplification is available from Clontech. Suitable primers for 5' and 3' RACE can be deduced from sequences of amplified cDNAs obtained during the initial PCR with degenerate primers described above or from sequences of cDNA clones obtained by screening cDNA or genomic DNA libraries . In the preferred embodiment, primers for nested PCR, designed according to the 5' end of a 1.6 kb cDNA isolated from the plate screening, were: Primer 4 5 ' -TGTGGTGTCTGGGCTGCTCTCAGATGC-3 ' (SEQ ID NO: 8) Primer 5 5 ' -ACTGTCTGCTTGGTCCAGTCTCTGG-3 ' (SEQ ID NO : 9) . For 3 ' -degenerate PCR, suitable nested primers correspond to sequences at the 3 ' end of a cDNA isolated from plate screening and a suitable degenerate primer corresponds to a conserved sequence found in BMP-1/tolloid- like proteins in CUB domain 5. Suitable primers include: Primer 6 5 • -TACCTGGAAGTCCGGGATGGCCCCACG-3 ' (SEQ ID NO: 10) Primer 7 5 ■ -GAGGATGTGAAATCGAGCTCCAACAGAC-3 ' (SEQ ID NO : 11 ) Primers 8-11 (degenerate primer) 5 ' -RAANCCYTTYTTNNNDATNGTRTCRTC-3 ' (SEQ ID NO: 12) For 3' RACE, suitable nested PCR primers corresponding to the sequences at the 3 ' end of the cDNA fragment amplified using 3 ' -degenerate PCR are: Primer 12 5 ' -CAACAACTACCCGAGCGAGGCCCC-3 ' (SEQ ID NO: 13) Primer 13 5 ' -GAAGCCTACGACGGCTACGACAGCTC-3 ' (SEQ ID NO: 14) . One of ordinary skill in the art can join the separate cloned sequences together, as the inventors have done, to produce the complete full-length cDNA obtained from a human, as shown in SEQ ID NO:l. Presented herein in SEQ ID NO:l is an open reading frame flanked by 5'- and 3'- untranslated sequences. The open reading frame encodes a mammalian tolloid-like protein termed mTll-2. The human mTll-2 gene maps to human chromosome 10q24. A second mTll-2 gene, obtained from a murine source, is shown in SEQ ID NO: 3. A corresponding protein encoded by the murine mTll-2 gene is reported at SEQ ID NO : 4. The murine version corresponds to the human mTll-2 gene in that the two share similar nucleic acid and amino acid sequences. The murine mTll-2 gene has not yet been mapped to a region of the murine chromosome . A preparation of polynucleotide (e.g., DNA) molecules containing an mTll-2 gene sequence from any source is considered substantially pure if more than 90% of any cellular material of any host cell in which the DNA has resided has been removed from the DNA preparation. Cellular material can be removed from a nucleic acid preparation, for example, by using a commercial purification kit such as is available from Qiagen (Chatsworth, CA) . It is preferred that greater than 10% of the nucleic acid molecules in a nucleic acid preparation comprise the complete or partial mTll-2 gene. More preferably, greater than 50%, and yet more preferably, greater than 90%, of the nucleic acid molecules comprise the complete or partial sequence. In view of the similarity to other tolloid-like proteins, it is expected that the product encoded by the disclosed mTll-2 gene will have a key role in development and in homeostatic processes such as wound healing. The protein is involved in maturation of extracellular matrix precursors into macromolecular structures, e.g., by activating prolysyl oxidase. The protein may also have a role in activation of growth factors in vivo and in vi tro, and may accelerate developmental and homeostatic processes when an effective amount of the protein is administered to a tissue. On the other hand, if the mTll-2 protein function is inhibited, such processes may themselves be inhibited, which property can be exploited advantageously upon delivery of an effective amount of an inhibitor to prevent fibrosis and excess scarring or other abnormalities of wound healing. An effective amount of the protein to be delivered to a target site for activating developmental and homeostatic properties can readily be determined by testing a range of amounts of the protein on a selected veterinary species or on a model species having acknowledged biochemical or physiological similarity to humans. In the case of skin or heart wound healing or development, for example, porcine skin or heart is a suitable model for human skin or heart. Rat or rabbit heart are also acceptable systems. Likewise, an effective amount of an inhibitor of the mTll-2 protein can also be determined. An effective amount is an amount effective upon administration that reduces the occurrence of fibrosis, scarring or keloids compared to an untreated animal, where the assessment of such conditions is made according to accepted clinical or veterinary standards. Such a test is preferably performed in a model system generally accepted as having relevance to human skin, heart or other affected tissue. The ability to work with proteins of the BMP system has been hampered by the fact that the proteins are typically present in very small amounts in animal tissues. mTll-2, a previously unknown gene, can be cloned into a suitable expression vector containing a transcriptional promoter effective in a suitable mammalian or insect host cell, introduced into and expressed in the suitable host cells, and purified in a native configuration, all using conventional methods. The cDNA can be inserted into an integratable (e.g., a pCDNA3.1-type) or episomal (e.g., a pCEP4-type) vector and expressed in suitable cultured mammalian cells (e.g., 293 human embryonic kidney cells or 293-EBNA cells, respectively). The pCDNA3.1 and pCEP4 vectors (and related vectors) are commercially available from Invitrogen. Vector sequences and restriction maps of the vectors are also available from Invitrogen. The cDNA can also be inserted into a baculovirus vector (e.g., BacPAK 6, commercially available from Clontech) . The protein thus expressed can remain inside the host cell or can be secreted to the extracellular growth medium, if a suitable signal sequence is provided on the construct. The protein can be purified from the cell or from the growth medium by conventional methods. The recombinant protein (and its cognate mRNA) can be used for functional assays and for high throughput screening of inhibitors. The recombinant protein and portions of the protein can be produced from subclones of the sequences disclosed herein and can be used for x-ray crystallography for rational drug design. Antibodies specific to the mTll-2 protein can be designed. Suitable promoters of transcription include cyotomegalogvirus immediate early promoter such as is found in the pCDNA3.1 or pCEP vectors, or the baculovirus very late promoter found on vector pFASTBacl, which vector is commercially available from Gibco-BRL. Another suitable promoter is baculovirus immediate early promoter such as is found on the pAcPIEl vector (Novagen, Madison, WI) . Any other advantageous expression elements such as enhancers, terminators, and the like, as are known to the art, can be included on the suitable expression vector. A suitable host would be insect tissue culture cells, such as cell line Sf21, Sf9, High Five (Invitrogen, San Diego, CA) , or mammalian 293 or 293-EBNA cells. Suitable portions of the gene comprising less than the full coding sequence can also be advantageously cloned into the suitable expression vector to form a recombinant genetic construct . It is understood that a construct prepared in accordance with the invention, need not necessarily contain the entire mTll-2 locus or coding region, but could contain one or more portions thereof encoding a desired function, or containing a portion of the gene having other useful properties, for example, complementarity to a desired genomic sequence. It is understood by those of ordinary skill that certain variation in the size or sequence of the mTll-2 protein (and in the corresponding genetic material encoding the mTll-2 protein) will not interfere with the functions thereof. Such modified forms can be engineered using known methods that may be advantageously employed when constructing genetic constructs containing the complete or partial mTll-2 gene, and in proteins encoded thereby. Such changes, modifications, additions and deletions are contemplated to fall within the scope of the present invention, as long as the protein retains a desired function known to be associated with the protein. The protein is competent if it retains an ability to cleave, e.g., prolysyl oxidase, in a standard assay for such cleavage. One of ordinary skill is familiar with the necessary controls that should accompany any such assay. It may, alternatively, be desired that the protein lose a certain function as a result of such a change, and such a situation is also envisioned to be within the scope of the present invention. A substantially pure preparation of the protein thus produced is defined as a preparation wherein the characteristic activity of the mTll-2 protein (such as weak cleavage of prolysyl oxidase) is not affected by the presence of other proteins or molecules in the preparation. Depending upon the use to which the protein will be put, it may be that the mTll-2 protein accounts for at least 10%, preferably at least 50%, more preferably at least 75%, and most preferably at least 95% of the protein in the substantially pure protein preparation. The protein preparation can be enhanced for the protein of interest by labeling the protein with an affinity tag and passing the preparation over a column having an affinity for the tag. It is also possible to employ a processing tag such that a properly processed form of the protein (lacking the cleaved proregion) can be eluted from a column loaded with a crude preparation. When the murine mTll-2 protein sequence is compared to other tolloid-like genes, no extensive homology exists between it and the proregion of either of the two mammalian proteins (mTld and mTll) or the proregion of either of the two Drosophila proteins (Tld or Tlr-1) . Fig. 1 aligns the amino acid sequences of the disclosed human and murine mTll-2 genes to those of the human mTld and human mTll-1 genes. Alignment was performed using the PileUp program (Genetics Computer Group, Madison, Wisconsin) , with a GAP weight of 12 and GAP length weight of 4. Fig. 1 also notes the approximate boundaries of the various domains of the proteins encoded by the indicated coding sequences . The amino acid sequences presented in Fig. 1 are, from top to bottom, human mTll-2, mouse mTll-2, mTld, and mTll-1, respectively . The mTll-2 mRNA transcript appears not to be alternatively spliced since only a single transcript was detected and because only a single type of mTll-2 cDNA was isolated during cDNA library screenings and PCR amplifications in each species. Relatively strong mTll-2 mRNA expression was observed in placenta and heart . It is specifically envisioned that equivalents of the mTll-2 gene can be isolated from other species, by probing a cDNA library from cells of an appropriate species with a probe selected to include an mTll-2-specific portion of the described mouse gene or by PCR amplification with degenerate primers similar to, or differing from, those described above. An mTll-2 -specific portion of the mouse mTll-2 gene can be obtained by comparing the nucleic acid sequence of the mouse mTll-2 coding region to that of BMP- 1/mTld and mTll-1 and selecting a portion of the mTll-2 gene that has no equivalent in either gene. To be an effective probe, the selected sequence should not contain repeat sequences that would cross-hybridize to numerous genomic sites. The probe should be at least about 200 bases long. It is recognized that the genes of the BMP-1 family are most variable in the regions that encode the proregion and the C-terminal 17 amino acids of the proteins, and it is anticipated that suitable probes can be isolated from those regions of the mTll-2 gene. Such a probe fragment can be converted into a probe by nick translation, end labeling, or other suitable technique known to the art. It is also understood that a desired fragment (or indeed an entire gene) can be synthesized in vi tro using well-known techniques available to the molecular biologist. One skilled in the art can design degenerate primers that correspond to regions either unique to mTll-2 or conserved among members of the BMP-1/mTll- l/mTll-2 family of proteins. Because defects in mTll-2 may lead to genetic abnormalities in people, the chromosomal position (10q24) of the human TLL-2 gene was established as described below in the Examples. This location is near the map position associated with a human genetic condition, spastic paraparesis with amyotrophy. The TLL-2 gene was independently mapped by fluorescence in situ hybridization (FISH) on human metaphase chromosome spreads by the method of Trask, B., Methods Cell Biol. 35: 1-35 (1992) and by radiation hybrid screening. It should also be possible to use PCR to amplify a portion of a genome that corresponds to the mTll-2 region, by selecting specific primers expected to flank the mTll-2 gene (or any portion of the gene) . Two mTll-2-specific portions of the gene can serve as suitable primers. It may not be effective to select primers outside the coding portion of the gene because reduced selective pressure on non-coding portions results in greater divergence between mice and humans and other species in those regions. It is specifically noted that the genes of the BMP family from humans and model species such as the mouse are particularly sought after for their relation to human deformities (see, e.g., "The Chicken With a Duck's Feet: It's All in the Biochemical Signal," The New York Times . National Edition, p. B6 (May 21, 1996) ) . It is also specifically envisioned that large quantities of the protein encoded by the mTll-2 gene can be expressed in (or secreted from) host cells, purified to a substantially pure preparation and used in subsequent functional assays. In one such functional assay, functional attributes of the expressed protein will be described. The protein functions are expected to include a metalloprotease activity, and prolysyl oxidase processing activity, and an activating activity for TGF-β-like proteins, such predictions being reasonable in view of the gross structural similarity to known proteins at the domain level. In another assay, the protein can be used to screen putative agents having inhibitory activity against the protein. Given that mTll-2 may be able to rescue BMP-1 knockout mice, it will be important for any therapeutic system that modifies or eliminates BMP-1 protein function to similarly alter the mTll-2 protein function. Thus, any panel of such agents must be screened against mTll-2 protein. In such an assay, all components of an assay that support mTll-2 function can be added together, under suitable conditions of salt and pH, and combined with a panel of putative inhibitors of protein function. Using established assays of protein function (described in documents incorporated elsewhere herein by reference) , it will be possible to determine whether any tested agent can inhibit protein activity, thereby making it a likely candidate for use in a therapeutic amount to inhibit fibrosis, or to reduce scarring, or reduce keloids . Such screening efforts are underway using related proteins from the BMP-1 family of genes. It is now also possible to embark upon a rational drug design strategy using the disclosed protein or fragments thereof. In doing so, the protein or fragments will be subjected to x-ray crystallographic analysis to determine their active sites and sites that are available for interaction with a putative therapeutic agent . The protein encoded by BMP-1 was recently shown to cleave procollagen near the C-terminus. This C-proteinase activity, which is essential to the production of collagen, had long been thought to reside in a protein that had remained elusive. There is great commercial interest in harnessing the C-proteinase activity as a therapeutic agent in collagen-related diseases. It is specifically contemplated that parts of the protein encoded by mTll-2 can be used in an effort to produce an alternative C- proteinase and, both by incorporating the gene into a recombinant vector for ex vivo production of therapeutic protein, and for direct administration in a genetic therapy. The human gene has particular utility for these applications . The invention will be better understood upon consideration of the following non-limiting Examples. EXAMPLES Human mTll-2 from human placental cDNA PCR amplification using degenerate primers. A portion of an mTll-2 gene was amplified from a human placental Marathon-Ready cDNA library (Clontech) using degenerate primers that corresponded to a pair of regions that are conserved in catalytic domains of BMP-1/tolloid-like astacin metalloproteases (see Bond, J.S. and R. J. Benyon, Protein Science 4:1247-1261 at 1249 (1995), incorporated herein by reference) . To determine a suitable sequence for the degenerate primers, the corresponding nucleotide sequences of human (Wozney et al . , 1988), mouse (Fukagawa et al., 1994) and Xenopus (Ma_no et al . , 1993) BMP-1; Drosophila tolloid-related-1 (Nguyen et al . , 1994); and mouse (Takahara et al . , 1996) and human mTll-1 were manually aligned. A pair of 5' (forward) oligonucleotide primers denoted Primer 1 : 5 • -CARGCMATGMGNCACTGGGAG-3 ' (SEQ ID NO: 5) and Primer 2 : 5 ' -CARGCMATGMGNCACTGGGAA-3 ' (SEQ ID NO: 6) corresponds to a sequence that encodes the more amino-terminal amino acid conserved residues AMRHWE . The two forward primers differ only at the most 3 ' base corresponding to the wobble position of a codon for E. A 3' (reverse) oligonucleotide primer denoted Primer 3:5'- GAADGTGTTVCKNGCRTARTGC-3 ' (SEQ ID NO: 7) corresponded to a sequence that encodes the more carboxy-terminal amino acid conserved residues HYARNTF. The PCR was performed with denaturation at 95°C/5 min, followed by 30 cycles of 95°C/45 s, 50°C/45 s, 72°C/2 min, and final extension at 72°C/10 min, using 0.5 ng of the human placenta cDNA as template. A heterogeneous 375 bp PCR product observed upon electrophoresis was excised from a 2% agarose gel and was then ligated into the commercially available pCR 2.1 vector (Invitrogen) , the nucleic acid sequence of which is published. The ligation reaction was restricted with Apal, which cleaves within BMP-1/mTld sequences, to reduce the background of BMP-1/mTld clones. Sequence analysis of clones revealed a PCR product of about 375 bp obtained using primer 2 in combination with primer 3. No mTll-2 or other novel (eg. non-BMP-1/mTld or mTll-1) products were obtained using primer 1 in combination with primer 3. The human mTll-2 sequences reported herein were confirmed by sequencing both strands. cDNA Library Screening. The 375 bp human mTll-2 PCR fragment was radiolabeled with 32 P-dCTP (Amersham) by random priming (Feinberg, A. P., and Vogelstein, B. (1983). A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6- 13, incorporated herein by reference in its entirety) and was used to screen plaques of a gtll human placenta cDNA library (Clontech) . Hybridization was at 65 °C for 18 h with washing in 2 x SSC, 0.1% SDS for 30 min at room temperature; in 2 x SSC, 0.1% SDS for 30 min at 65 °C; and in 0.1 x SSC, 0.1% SDS for 30 min at 65 °C. One strongly hybridizing positive was plaque purified and an insert of about 1.6 kb (corresponding approximately to the proregion, catalytic, CUBl, and CUB2 domains typical of genes in the BMP-1 family) was excised, subcloned into the EcoRI site of pBluescript II KS + and sequences were obtained from double-stranded templates by dideoxy chain termination, as described in Lee S.-T., et al . , "Construction of a full-length cDNA encoding human pro- alpha 2(1) collagen and its expression in pro-alpha 2(1)- deficient W8 rat cells," J. Biol. Chem. 263:13414-13418 (1988) , incorporated herein by reference in its entirety. Ends of subclones were sequenced using T3 and T7 primers with internal portions of subclones made accessible to sequencing by introducing deletions or using primers complementary to insert sequences. Further attempts at plate screening failed to generate additional positive clones encoding novel mTll-2 sequences. RACE-PCR and PCR with degenerate primers for completing the 5 1 and 3' ends of human mTll-2 cDNA sequences. To obtain all sequences between the 1.6 kb fragment (obtained as described above) and the mTll-2 cDNA 5' end sequences, 5' RACE PCR amplification of 0.5 ng of human placenta Marathon-Ready cDNA template was performed using the Marathon cDNA Amplification Kit, using the manufacturer's instructions (Clontech) . Nested primers that correspond to sequences near the 5 ' -end of the 1.6 kb fragment are Primer 4: 5'-TGTGGTGTCTGGGCTGCTCTCAGATGC-3' (SEQ ID NO: 8) and Primer 5: 5 ' -ACTGTCTGCTTGGTCCAGTCTCTGG-3 ' (SEQ ID NO: 9). The remaining primers in the nested PCR reactions correspond to portions of the RACE-PCR adaptors synthesized by Clontech and included in the commercially available Marathon cDNA amplification kit, which is used to perform the process of nested PCR. Nested-PCR was performed, with the first round of PCR performed at 95°C/5 min, followed by 40 cycles of 95°C/45 s, 60°C/45 s, 72°C/2 min and final extension at 72°C/10 min. The second, nested round of PCR was performed under identical conditions except that 35, rather than 40 cycles, were employed. PCR products were cloned into the Invitrogen pCR 2.1 vector for sequence analysis. An approximately 900 bp mTll-2 5' RACE-cDNA clone was obtained that encoded part of the proregion and all of the signal peptide, and contained about 360 bp of 5' untranslated sequences. Initially, 3 ' RACE PCR did not provide additional 3 ' sequences of the human mTll-2 gene. Therefore, an intermediate PCR amplification step was employed using two nested primers (primer 6: 5 ' -TACCTGGAAGTCCGGGATGGCCCCACG-3 ' (SEQ ID NO: 10) and primer 7, 5'- GAGGATGTGAAATCGAGCTCCAACAGAC-3' (SEQ ID NO: 11)) corresponding to sequences at the 3 ' end of the 1.6 kb cDNA and four alternative degenerate oligonucleotide primers corresponding to an amino acid sequence conserved in CUB domain 5 of human and mouse mTld and mTll-1 proteins. The degenerate reverse primers 8-11 share the sequence 5'- RAANCCYTTYTTNNNDATNGT-3 ' , but six additional 3' end bases varied among each primer. The terminal sequences of reverse primers 8-11 are: primer 8, 5 ' -GTCGTC-3 ' ; primer 9, 5 ' -ATCATC-3 ' ; primer 10, 5 ' -GTCATC-3 ' ; and primer 11, 5'- ATCGTC-3 ' . These four degenerate primers are listed as a single degenerate primer in SEQ ID NO: 12, wherein the variation among primers 8, 9, 10 and 11 are reflected in the degeneracy in the six 3 ' -most bases. Human placenta Marathon-Ready cDNA was used as template (0.5 ng) . The first round of PCR was performed at 95°C/5 min followed by 40 cycles of 95°C/45 s, 60°C/45 s, 72°C/4 min, with final extension at 72°C/10 min. The second, nested round of PCR was performed under identical conditions except that 35, rather than 40 cycles were employed. A specific product of approximately 1.3 kb was excised from a 0.8% agarose gel and was cloned into pCR 2.1 for sequence analysis. The 1.3 kb fragment encoded all of the EGF1, CUB3, EGF2 , and CUB4 domains and most of the CUB5 domain of human mTll-2 and was obtained using degenerate reverse primer 10, but not primers 8,9 or 11, in combination with nested forward primers 6 or 7. To obtain the remaining human mTll-2 cDNA sequences, a 3' RACE PCR was performed using two nested primers corresponding to sequences near the 3 ' -end of the 1.3 kb fragment (Primer 12, 5 ' -CAACAACTACCCGAGCGAGGCCCG-3 ' (SEQ ID NO: 13) and primer 13, 5 ' -GAAGCCTACGACGGCTACGACAGCTC-3 ' (SEQ ID NO: 14)), 0.5 ng human placenta Marathon-Ready cDNA as template (0.5 ng) , and the Marathon cDNA Amplification Kit, using the manufacturer's instructions (Clontech). Nested- PCR was performed, with the first round of PCR performed at 95°C/5 min followed by 40 cycles of 95°C/45 s, 60°C/45 s, 72°C/4 min, and final extension at 72°C/10 min. The second, nested round of PCR was performed under identical conditions except that 35, rather than 40, cycles were employed. A specific product of approximately 1.7 kb (encoding part of the CUB5 domain and containing 1.6 kb of 3' untranslated region, including a poly A tail) was excised from a 0.8% agarose gel and cloned into pCR 2.1 for sequence analysis. Murine mTll-2 The same degenerate primers and PCR conditions used to obtain the initial human 375 bp fragment (see above) were used to obtain a heterogeneous product of about 375 bp from mouse cDNA. In this case, the template used was 0.5 ng 7 day post coitus (dpc) mouse embryo Marathon-Ready cDNA (Clontech) . The 375 bp PCR product was electrophoresed, excised from a 2% agarose gel, ligated into pCR 2.1, and the ligation reaction restricted with Apal to reduce the background of BMP-1/mTld clones. In contrast to human sequences, a 375 bp mTll-2 PCR product was obtained using primer 1, in combination with primer 3, but no mTll-2 or other novel products were obtained using primer 2 in combination with primer 3. Screening of murine 7 dpc and 17 dpc cDNA libraries with the 375 bp fragment failed to generate any positive mTll-2 clones. To obtain all sequences between the 375 bp fragment and the 5' end of murine mTll-2 cDNA sequences, 5 ' RACE PCR was performed using degenerate reverse primer 3 (above) and a nested primer (primer 14, 5'- GCTTTCCTCATCTGTCCTCTCTACG-3' (SEQ ID NO: 15)) corresponding to sequences near the 3 ' -end of the 375 bp fragment, 0.5 ng of 7 dpc mouse embryo Marathon-Ready cDNA as template, and the Marathon cDNA Amplification Kit, using the manufacturer's instructions (Clontech). Nested-PCR was performed, with the first round of PCR performed at 94°C/30 s, followed by 5 cycles of 94°C/5 s, 72°C/4 min; 5 cycles of 94°C/5 s, 70°C/4 min; 30 cycles of 94°C/5 s, 68°C/4 min and final extension at 72°C/10 min. The second, nested round of PCR was performed at 94°C/30 s, followed by 5 cycles of 94°C/5 s, 72°C/4 min; 5 cycles of 94°C/5 s, 70°C/4 min; 25 cycles of 94°C/5 s, 68°C/4 min and final extension at 72°C/10 min. PCR products were cloned into Invitrogen pCR 2.1 vector for sequence analysis. A -900 bp mTll -2 PCR product was obtained that encoded part of the protease domain, all of the signal peptide and proregion and contained -200 bp of 5' untranslated sequences. To obtain sequences between the 375 bp fragment and the 3' end of murine mTll-2 cDNA sequences, 3' RACE PCR was performed using degenerate forward primer 1 (above) and a nested primer (primer 15, CCTGTGTGACCTTCGTAGAGAGG-3' (SEQ ID NO: 16) corresponding to sequences near the 5' end of the 375 bp fragment. PCR conditions were identical to those used for 5' RACE of murine mTll-2 sequences (above) . PCR products were cloned into pCR 2.1 for sequence analysis. A -1,200 bp mTll-2 PCR product was obtained the encoded part of the protease domain, all of domains CUBl, CUB2 , EGF1, CUB3 , EGF2 and ended within the CUB3 domain. The remaining portions of the coding sequence were amplified by PCR using oligonucleotide primers designed using sequence information obtained from the 1200 bp fragment. The full length coding region of the murine mTll-2 gene has been determined and occurs between bp 191 and 3229 or SEQ ID NO: 3. Chromosomal Assignment. TLL2 mapping was performed by radiation hybrid mapping (Walter et al . , 1994) involving polymerase chain reaction (PCR) analysis of the Genebridge 4 radiation hybrid panel, obtained from Research Genetics. Forward primer 5 ' -TGGGAGCTGAGCAATGCTAACTGC-3 ' (SEQ ID NO: 17) and reverse primer 5 ' -GAAGGTGTTCCGGGCGTAGTGCAT-3 ' (SEQ ID NO:18), corresponding to sequences in TLL2 intron 6 and exon 7, respectively, yielded a 1.4 kb PCR product with human genomic DNA template, but no product with control Chinese hamster genomic DNA template . The PCR was performed with 100 ng of template DNA and 10 pmoles of each primer with a thermocycler program of 95 °C for 5 min, followed by 30 cycles of 95°C/45 s, 65°C/45 s, 72°C./3 min and final extension at 72°C/10 min. PCR products were electrophoresed on a 0.8% agarose gel, visualized with ethidium bromide and the scoring submitted to the WICGR Mapping Service at the Whitehead Institute/MIT Center for Genome Research. TLL2 clearly mapped on the GeneBridge 4 Panel radiation hybrid set to chromosome lOq, 8.66 cR from marker D10S571 with a Lod score of 15. Additionally, TLL2 was mapped to chromosome 10 by fluorescence in situ hybridization (FISH) on male metaphase chromosome spreads by the method of Trask (1991) . A 10 kb BamHI genomic fragment containing TLL2 exons was subcloned into pBluescript II KS+ and labeled with digoxygenin-11-dUTP (Boehringer Mannheim) by random priming. Images were obtained and analyzed as described (Takahara et al . 1994) . Double fluorescent signals on both chromosomes were found only at 10q24 in 75% of metaphase spreads examined (15/20) and on no other chromosome (not shown) localizing TLL2 to this region. Tissue Sections for in situ Hybridization Tissue sections will be mounted on slides for in si tu hybridization. Mouse tissues will be fixed and embedded, as in Lyons et al . , "The expression of myosin genes in developing skeletal muscle," J. Cell Biol. 111:1465-1476 (1990) . Briefly, tissues are fixed in 4% paraformaldehyde in phosphate-buffered saline, dehydrated, and infiltrated with paraffin. Serial sections, 5-7 μm thick, are mounted on gelatinized slides. One to three sections are mounted/slide, deparaffinized in xylene, and rehydrated. Sections are digested with proteinase K, post-fixed, treated with tri-ethanolamine/acetic anhydride, washed, and dehydrated. In si tu hybridization and Washing Procedures Sections are hybridized overnight at 52 °C in 50% deionized formamide, 0.3 M NaCl, 20 mM Tris-HCl, pH 7.4 , 5 mM EDTA, 10 mM NaP0 4 , 10% dextran sulfate, 1 x Denhardt ' s solution, 50 μg/ml total yeast RNA, 25 μmol/ml thio-ATP (Boehringer-Mannheim) , and 50-75,000 cpm/μl 35 S-labeled cRNA probe. Tissue is stringently washed at 65°C in 50% formamide, 2 x SSC, 10 mM dithiothreitol; rinsed in phosphate-buffered saline; and treated with 20 μg/ml RNase A at 37°C for 30 min. Following washes in 2 x SSC and 0.1 x SSC for 15 min at 37°C, slides are dehydrated, dipped in Kodak NTB-2 nuclear track emulsion, and exposed for 1 week in light-tight boxes with desiccant at 4°C. Photographic development is in Kodak D-19. Slides are analyzed using light- and dark-field optics of a Zeiss Axiophot microscope. Subcloninσ and expression of mTll -2 σene The mature active forms of BMP-1, mTld, mTll-1 and mTll-2 are all similar in their amino acid sequences. An exception to this is the C-terminus of each protein, where no homology is observed. This uniqueness of C-terminal sequences can been put to use in producing a set of polyclonal antibodies capable of discriminating between the protein forms. In the case of mouse mTll-2, a synthetic peptide that corresponds to the final 17 amino acids of mTll-2 can be linked to the protein carrier Keyhole Limpet Hemocyanin, suspended in saline and emulsified by mixing with an equal volume of Freund's adjuvant and injected into three to four subcutaneous dorsal sites in each of two rabbits. Bleeds for sera are at 12 and 16 weeks after immunization and boosts. Such antibodies have commercial utility in an assay for visualizing the production and localization of mTll-2 protein in cells, tissues, and mammalian organisms, including, but not limited to model systems (e.g., rodents, primates, and the like) as well as humans . It should be noted that unique sequences exist in the protease, CUB and proregions of these proteins and can be used to detect and distinguish among the various members of the family. See, Lee, S. J. Biol. Chem. 272:19059-19066 ( 1997 ) . In view of the rapid pace at which the understanding of the bone morphogenetic proteins is advancing, the ability to distinguish individual components one from another is important, not merely from a research perspective, but in monitoring the level and distribution of BMP system components in patients having disorders of the BMP system. Such disorders could include, for example, in mice and humans, fibrotic conditions or heart disease. In addition, hereditary developmental abnormalities may be due to defects in the TLL2 gene. Determining the role of mTll-2 in such genetic abnormalities will be enabled by the antibody and nucleic acid probes described herein. The mTll-2 protein is quite clearly important in organism development, in that it is expressed in placenta and in the developing heart .

Claims: CLAIMS We claim: 1. An isolated polynucleotide comprising a nucleotide sequence amplifiable in a polymerase chain reaction using a first degenerate amplification primer comprising a sequence of SEQ ID NO: 7 and a second degenerate amplification primer comprising a sequence selected from the group consisting of SEQ ID NO : 5 and SEQ ID NO: 6, wherein the polynucleotide is not cleaved by Apal. 2. A polynucleotide as claimed in claim 1 wherein the polynucleotide is obtainable from a human. 3. A polynucleotide as claimed in Claim 2 comprising a sequence of nucleotides 365 to 3409 of SEQ ID NO : 1. 4. A polynucleotide as claimed in Claim 3 comprising a sequence of SEQ ID NO:l. 5. A polynucleotide as claimed in claim 1 wherein the polynucleotide is obtainable from a mouse. 6. A polynucleotide as claimed in Claim 5 comprising a sequence of nucleotides 191 to 3229 of SEQ ID NO: 3. 7. A polynucleotide as claimed in Claim 4 comprising a sequence of SEQ ID NO: 3. 8. A genetic construct comprising a transcriptional promoter operably linked to a polynucleotide that comprises a nucleotide sequence amplifiable in a polymerase chain reaction using a first degenerate amplification primer comprising a sequence of SEQ ID NO: 7 and a second degenerate amplification primer comprising a sequence selected from the group consisting of SEQ ID NO : 5 and SEQ ID NO: 6, wherein the polynucleotide is not cleaved by Apal. 9. A genetic construct as claimed in claim 8 wherein the polynucleotide is obtainable from a human. 10. A genetic construct as claimed in Claim 9 comprising a sequence of nucleotides 365 to 3409 of SEQ ID NO : 1. 11. A genetic construct as claimed in Claim 10 comprising a sequence of SEQ ID NO:l. 12. A genetic construct as claimed in claim 8 wherein the polynucleotide is obtainable from a mouse. 13. A genetic construct as claimed in Claim 12 comprising a sequence of nucleotides 191 to 3229 of SEQ ID NO: 3. 14. A genetic construct as claimed in Claim 12 comprising a sequence of SEQ ID NO: 3. 15. A polypeptide comprising a sequence selected from SEQ ID NO: 2 and SEQ ID NO:4. 16. A method for selecting an agent that modulates an activity of mTll-2 protein, the method comprising the steps of: evaluating the activity of the mTll-2 protein under conditions that support mTll-2 protein function, with and without one or more putative modulators of the activity; and selecting an agent from the one or more putative modulators that modulates the activity of the protein relative to the activity of the protein without the agent.

Inventors: GREENSPAN DANIEL S, SCOTT IAN C, THOMAS CHRISTINA L, GREENSPAN, DANIEL, S., SCOTT, IAN, C., THOMAS, CHRISTINA, L.
Applicants: WISCONSIN ALUMNI RES FOUND, WISCONSIN ALUMNI RESEARCH FOUNDATION
Application year: 1999
Main classification: C12N15
IPC codes: A61K38, C07K14, C12N15, G01N33